Novel anticoagulants based on direct inhibition of thrombin and factor Xa

Coronary Artery Disease

Volumn 9, Issue 2-3, 1998, Pages 75-81

  Gardell, Stephen J ^a   Sanderson, Philip E J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anticoagulants; Factor Xa; Inhibition; Thrombosis

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; HIRUDIN; HIRULOG; THROMBIN; THROMBIN INHIBITOR;

PRIORITY JOURNAL; REVIEW;

EID: 0031861523     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199809020-00003     Document Type: Review

References (67)

1. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. Circulation 1994, 89:1449-1468.
2. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. Circulation 1994, 89:1469-1480.
3. Davie, EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991, 30:10363-10370.
4. Zoldhelyl P, Webster MW, Fuster V, Grill DE, Gaspar D, Edwards SJ, et al Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993, 88:2015-2022.
5. Lidón R-M, Théroux P, Juneau M, Adelman B, Maraganore J. Initial experience with a direct antithrombin, hirulog, in unstable angina. Circulation 1993, 88:1495-1501.
6. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
7. Vlasuk GP. Direct factor Xa inhibitors. In: Sasahara AA and Loscalzo J, editors. New therapeutic agents in thrombosis and thrombolysis. Marcel Dekker Inc.: New York; 1997. pp. 261-283.
8. Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 1993, 69:1-58.
9. Markwardt F. Past, present and future of hirudin. Haemostasis 1991, 21:11-26.
10. Rydal TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, et al. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990, 249:277-280.
11. Märki WE, Wallis RB. The anticoagulant and antithrombotic properties of hirudins. Thromb Haemost 1990, 64:344-348.
12. Noeske-Jungblut C, Haendler B, Donner P, Alagon A, Possani L, Schleuning W-D. Triaban, a highly potent exosite inhibitor of thrombin. J Biol Chem 1995, 48:28629-28634.
13. Maraganore JM, Bourdon P, Jablonski J, Ramachandran, KL, Fenton JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990, 29:7095-7101.
14. Maraganore JM. Hirudin and hirulog. Advances in antithrombotic therapy. Perspect Drug Discov Design 1993, 1:461-478.
15. Lyle TA. Small-molecule inhibitors of thrombin. Perspect Drug Discov Design 1993, 1:453-460.
16. Tapparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol Sci 1993, 14:366-376.
17. Das J, Kimball SD. Thrombin active site inhibitors. Bioorg Med Chem 1995, 3:999-1007.
18. Mehdi S. Synthetic and naturally occurring protease inhibitors containing an electrophilic carbonyl group. Bioorg Chem 1993, 21:249-259.
19. Bajusz S, Szell E, Bagdy D, Barabas E, Horvath G, Diozegi M, et al. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J Med Chem 1990, 33:1729-1735.
20. Shuman RT, Rothenberger RB, Campbell CS, Smith GP, Gifford-Moore DS, Gesellchen PD. Highly selective tripeptide thrombin inhibitors. J Med Chem 1993, 36:314-319.
21. Brady SF, Sisko JT, Stauffer KJ, Colton CD, Qiu H, Lewis SD, et al. Amide and alpha-keto carbonyl inhibitors of thrombin based on arginine and lysine: synthesis, stability and biological characterization. Bioorg Med Chem 1995, 3:1063-1078.
22. Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990, 265:18289-18297.
23. Knabb RM, Luettgen JM, Leamy AW, Barbera FA, Kettner CA, Pangburn MJ, et al. Acute toxicity of synthetic thrombin inhibitors caused by inhibition of complement factor I. Circulation 1996, 94 (suppl I):I-696.
24. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2- piperidine carboxylic acid. Biochemistry 1984, 23:85-90.
25. Hijikata-Okunomiya A, Okamoto S. A strategy for a rational approach to designing synthetic selective thrombin inhibitors. Semin Thromb Hemost 1992, 18:135-149.
26. Fitzgerald D, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996, 7:455-458.
27. Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadváry P, et al. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem 1994, 37:3889-3901.
28. Teger-Nilsson AC, Bylund R, Gutstafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran, a selective LMW thrombin inhibitor. Thromb Res 1997, 85:133-145.
29. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998, 79:110-118.
30. Tucker TJ, Lumma WC, Mulichak AM, Chen Z, Naylor-Olsen AM, Lewis SD, et al. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J Med Chem 1997, 40:830-832.
31. Brady SF, Stauffer KJ, Lumma WC, Smith GM, Ramjit HG, Lewis SD, et al. Discovery and development of the novel potent orally active thrombin inhibitor N-(9-Hydroxy-9-fluorenecarboxy)prolyl trans-4-Aminocyclohexyl-methyl Amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J Med Chem 1998, 41:401-406.
32. Cousins GR, Friedrichs GS, Sudo Y, Rebello SS, Rote WE, Vlasuk GP. Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog. Circulation 1996, 94:1705-1712.
33. Vlasuk G. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993, 70:212-216.
34. Jordan SP, Mao S-S, Lewis SD, Shafer JA. Reaction pathway for inhibition of blood coagulation factor Xa by tick anticoagulant peptide. Biochemistry 1992, 31:5374-5380.
35. Krishnaswamy S, Vlasuk GP, Bergum PW. Assembly of the prothrombinase complex enhanced the inhibition of bovine factor Xa by tick anticoagulant peptide. Biochemistry 1994, 33:7897-7907.
36. Tuszynski GP, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. J Biol Chem 1987, 262:9718-9723.
37. Dunwiddie CT, Nutt EM, Vlasuk GP, Siegl PK, Schaffer LW. Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistasin following subcutaneous administration in the rhesus monkey. Thromb Haemost 1992, 67:371-376.
38. Harker LA, Hanson SR, Kelly AB. Antithrombotic benefits and haemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995, 74:464-472.
39. Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, et al. Structure of human des(1-45) factor Xa at 2-2Å resolution. J Mol Biol 1993, 232:947-966.
40. Brandstetter H, Kuhne A, Bode W, Huber R, von der Saal W, Wirthensohn K, et al. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J Biol Chem 1996, 271:29988-29992.
41. Hara T, Yokoyama A, Ishihara H, Yokoyama Y, Nagahara T, Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994, 71:314-319.
42. Hara T, Yokoyama A, Tanabe K, Ishihara H, Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995, 74:635-639.
43. Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995, 92:485-491.
44. Taniuchi Y, Sakai Y, Kawasaki T, Hisamichi N, Sato K, Kayama M, et al. Anticoagulant and pharmacokinetic profiles of YM-60828, an orally active and potent synthetic inhibitor of factor Xa. Thromb Haemost 1997, 77 (suppl):294.
45. Catella-Lawson F. Direct thrombin inhibitors in cardiovascular disease. Coran Artery Dis 1997, 8:105-111.
46. GUSTO IIa Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndrome. N Engl J Med 1996, 335:775-782.
47. Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction Trial. Circulation 1994, 90:1624-1630.
48. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Mauerer W, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994, 90:1638-1642.
49. Antman EM, for the TIMI 9B investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibiton in myocardial infarction (TIMI) 9B trial. Circulation 1996, 94:911-921.
50. GUSTO IIb Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994, 90:1631-1637.
51. Organization to Assess Strategies for Ischemic Syndromes (OASIS). Comparison of hirudin with heparin and warfarin with control for unstable angina and non Q wave MI in a randomized controlled trial. Circulation 1995, 92 (suppl I):I-416.
52. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995, 333:757-763.
53. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996, 347:635-639.
54. Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997, 79:326-333.
55. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995, 91:2132-2139.
56. White HD, Aylward PE, Frey MJ, Adgey AAJ, Nair R, Hillis WS, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997, 96:2155-2161.
57. Fuchs J, Cannon CP for the TIMI 7 Investigators. Hirulog in the treatment of unstable angina: results of the TIMI 7 trial. Circulation 1995, 92:727-733.
58. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995, 333:764-769.
59. Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, et al. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1994, 90:2385-2389.
60. Gold HK, Torres FW, Garabedian HD, Werner W, Jang OL, Khan A, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993, 21:1039-1047.
61. Schwarz RP Jr, Becker J-CP, Brooks RL, Hursting MJ, Joffrion JL, Knappenberger GD, et al. The preclinical and clinical pharmacology of novastatin (argatroban): a small-molecule, direct thrombin inhibitor. Clin Appl Thromb/Hemost 1997, 3:1-15.
62. Vermeer F, Vehanian A, Fels PW, Besse P, Radzik D, Simoons ML, et al. Intravenous argatroban versus heparin as co-medication to alteplase in the treatment of acute myocardial infarction; preliminary results of the ARGAMI pilot study. J Am Coll Cardiol 1997, 29 (suppl A):185A.
63. Lewis BE, Grassman E, Wrona L, Rangel Y, Iqbal O, Walenga JM, et al. Successful use of argatroban in coronary angioplasty in patients with heparin induced thrombocytopenia syndrome. Thromb Haemost 1997, 77 (suppl):494.
64. Jackson CV, Satterwhite J, Roberts E. Preclinical and clinical pharmacology of efegatran (LY294468): a novel antithrombin for the treatment of acute coronary syndromes. Clin Appl Thromb/Haemost 1996, 2:258-267.
65. Andersen K, Eriksson P, Kallstrom G, Alfvegren E, Dellborg M. Heparin is more effective than inogatran, a novel low-molecular weight thrombin inhibitor in unstable coronary disease. J Am Coll Cardiol 1997, 2 (suppl):1033-1044.
66. Bounameaux H, Ehringer H, Hulting J, Rasche H, Rapold HJ, Zultak M, et al. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis. Results of the European multicenter ADVENT trial. Thromb Haemost 1997, 78:997-1002.
67. Eriksson H, Eriksson UG, Frison L, Thorsen M. Intravenous treatment of acute deep venous thrombosis (DVT) with melagatran, a synthetic low molecular weight thrombin inhibitor. Thromb Haemost 1997, 77 (suppl):591.